| Overview |
| bs-15131R-PE |
| C22orf13 Polyclonal Antibody, PE Conjugated |
| WB |
| Human |
| Mouse, Rat, Dog, Horse |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human C22orf13 |
| 51-150/240 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 83606 |
| Nucleus |
| C22orf13; CG13760 gene product [Drosophila melanogaster] homolog; Chromosome 22 open reading frame 13; CV013_HUMAN; LLN4; MGC1842; OTTHUMP00000198388; Protein LLN4; Uncharacterized protein C22orf13. |
| Chromosome 22 contains over 500 genes and about 49 million bases. Being the second smallest human chromosome, 22 contains a surprising variety of interesting genes. Phelan-McDermid syndrome, Neurofibromatosis type 2 and autism are associated with chromosome 22. A schizophrenia susceptibility locus has been identified on chromosome 22 and studies show that 22q11 deletion symptoms include a high incidence of schizophrenia. Translocations between chromosomes 9 and 22 may lead to the formation of the Philadelphia Chromosome and the subsequent production of the novel fusion protein, BCR-Abl, a potent cell proliferation activator found in several types of leukemia. The C22orf13 gene product has been provisionally designated C22orf13 pending further characterization. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz